JMP Securities analyst Roy Buchanan initiated coverage of Gritstone Bio with an Outperform rating and $4 price target. Gritstone has an important Phase 2 readout for its lead GRANITE personalized cancer vaccine candidate in the coming weeks, the analyst tells investors in a research note. The firm gives the program a 50% overall probability of success and says Gritstone’s EDGE platform can provide broad benefits longer term, representing potential upside to the current valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on GRTS:
- Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
- Gritstone Oncology Postpones Phase 2b COVID-19 Vaccine Trial
- Gritstone announces update to comparative Phase 2b COVID-19 trial
- Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
- Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
